JPRN-UMIN000023393已完成未知
Optimal timing of pegfilgrastim in DCF regimen for advanced esophageal cancer - Optimal timing of pegfilgrastim in DCF regimen for advanced esophageal cancer
Kyoto Prefectural University of Medicine, Gatroenterology and Hepatology0 个研究点目标入组 23 人开始时间: 2016年8月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 23
研究概览
简要总结
The incidence of grade 4 neutropenia was 8.7 percent. No patient experienced FN. Of the 19 patients who received two cycles of DCF, one required a dose reduction/treatment delay due to hematological toxicity in the second treatment cycle. No serious adverse events, considered relevant to pegfilgrastim, were observed.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Synchronous or metachronous malignancies other than carcinoma in situ or mucosal carcinoma 2)Evidence of any other serious disease 3)Active local or systemic infection under treatment 4)History of serious allergic reaction 5)Pulmonary fibrosis or interstitial pneumonitis detected by chest X-ray 6)primary hematologic disease 7)Serious allergic reaction to Docetaxel, cisplatin, 5FU and pegfilgrastim 8)Massive pericardial effusion, pleural effusion or ascites 9)Received radiotherapy within 4 weeks before 10)Received drugs of other clinical tests within 4 weeks before 11)History of receiving pegfilgrastim before 12)Pregnant or lactating female 13)Judged inappropriate by the investigators
研究者
相似试验
进行中（未招募）
不适用
se of peg-filgrastim in severe chronic neutropeniaEUCTR2005-003096-20-ITISTITUTO GIANNINA GASLINI
招募中
4 期
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After ChemotherapyBreast NeoplasmsNCT05949333Eunseong Medical Foundation Good GANG-AN HOSPITAL100
已完成
2 期
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNCT00050674Schwartzberg, Lee, M.D.40
进行中（未招募）
1 期
Domestic Phase I/IIa Investigator-initiated Clinical Trials to Evaluate the Safety of 18F-PSMA-1007 in Healthy Adults and Subjects with Prostate CancerJPRN-jRCT2032210711Tateishi Ukihide13
已完成
2 期
A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving ChemotherapyNeutropeniaBreast CancerFebrile NeutropeniaNCT02119715Jiangsu HengRui Medicine Co., Ltd.182